In this episode of the Believe in Progress Podcast, our host Mitch Stoller, Chief Philanthropic Officer at the American Association for Cancer Research (AACR), speaks with two pioneering leaders from Novocure: Frank Leonard, Executive Vice President and President of Novocure Oncology; and, Dr. Moshe Giladi, Chief Science Officer. Novocure is at the forefront of revolutionizing cancer treatment with its groundbreaking Tumor Treating Fields (TTFIELDS®) therapy. Frank and Dr. Giladi share insights into how Novocure's innovative approach is changing the landscape of oncology and improving patient outcomes worldwide. The conversation begins with an overview of Novocure's mission and the mechanics of TTFIELDS® therapy, a unique approach to disrupting cancer cell division using electric fields. Dr. Giladi delves into the science behind TTFIELDS®, explaining its application across different cancer types and the therapy's integration with other treatments. Frank Leonard discusses the strategic vision for Novocure, highlighting the success of Optune Gio® and other recent advances. The episode also explores the significant impact of TTFIELDS® therapy on patient outcomes, including success stories and key milestones from clinical trials, such as the recent Phase III trial success in treating brain metastases of non-small cell lung cancer (NSCLC). Both guests emphasize the importance of collaboration, including the pivotal role of AACR-Novocure Cancer Research Grants in advancing TTFIELDS® research. Looking ahead, Frank and Dr. Giladi share their excitement about the future of TTFIELDS® therapy and upcoming research initiatives. They discuss the strategic priorities for Novocure, the potential expansion of TTFIELDS® therapy globally, and the evolving landscape of cancer treatment. Guest Bios and Episode Links: Frank Leonard is the Executive Vice President and President of Novocure Oncology. With over 15 years at Novocure, Frank has played a key role in the company's growth and its mission to advance cancer treatment through innovative therapies. Dr. Moshe Giladi is the Chief Science Officer at Novocure, overseeing the company's preclinical research and driving the development and acceptance of Tumor Treating Fields therapy. His work has been instrumental in validating the efficacy of TTFIELDS® in clinical settings. Learn more about Novocure and TTFIELDS® therapy: novocure.com To our listeners and followers: Your engagement and support help propel the AACR's mission forward. Please consider subscribing to our podcast, sharing this episode, and visiting AACR.org to learn how you can contribute to lifesaving cancer research. Every action counts in our collective effort to make a difference. Thank you for listening to Believe in Progress. Stories like those shared by Frank Leonard and Dr. Moshe Giladi remind us that progress isn't just about scientific advances; it's about the lives they touch and the hope they bring. Subscribe to our podcast for more episodes that celebrate the power of progress and the individuals who drive it. Remember: Supporting cancer research is crucial—every donation helps. Visit AACR.org to learn more and AACR.org/Donate to contribute to lifesaving research today. Let's continue to work together towards a world free from cancer. Cancer Research Saves Lives® Check out more episodes of Believe in Progress at AACR.org/BelieveInProgress. Listen and subscribe wherever you get your podcasts. This episode is produced by CollegeCast LLC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related